Bristol-Myers Squibb Reports Second Quarter Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Super Micro Computer establishes $1.25 billion stock sale agreement
Bristol-Myers Squibb Co. (BMY) PT Raised to $57 at BMO Capital
July 27, 2018 8:21 AM EDTBMO Capital raised its price target on Bristol-Myers Squibb Co. (NYSE: BMY) to $57.00 (from $51.00) while maintaining a Market Perform rating.
Analyst Alex Arfaei commented, "Bristol had a good 2Q but expectations had risen, which, coupled with untimely (CHMP RCC) news, pressured BMY. The... More
Bristol-Myers Squibb (BMY) Tops Q2 EPS by 14c; Raises Outlook
July 26, 2018 7:01 AM EDTBristol-Myers Squibb (NYSE: BMY) reported Q2 EPS of $1.01, $0.14 better than the analyst estimate of $0.87. Revenue for the quarter came in at $5.7 billion versus the consensus estimate of $5.48 billion.
We had a very good second quarter where we delivered strong performance for Eliquis and... More
